Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -88.35% | -125.98% | -95.93% | -91.88% | -- |
| Total Depreciation and Amortization | 103.17% | 241.38% | 495.97% | 883.78% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 434.38% | 336.08% | 152.06% | 16.98% | -- |
| Change in Net Operating Assets | 342.44% | 246.50% | 57.92% | -567.07% | -- |
| Cash from Operations | -62.48% | -80.07% | -79.85% | -115.40% | -- |
| Capital Expenditure | 81.09% | 49.94% | -194.77% | -810.08% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -44.31% | -- | -- | -- | -- |
| Cash from Investing | -38.81% | -6,758.67% | -21,797.76% | -59,427.73% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 437,045.83% | 10,486,000.00% | 10,448,100.00% | 10,448,100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,384.57% | -25,009.09% | -- | -- | -- |
| Cash from Financing | 2.73% | 2.36% | -4.04% | -9.37% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.72% | -158.73% | -172.73% | -171.51% | -- |